サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1405863

インフルエンザ治療の市場規模、シェア、動向分析レポート：治療薬別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年～2030年

Influenza Treatment Market Size, Share & Trends Analysis Report By Treatment (Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 130 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
インフルエンザ治療の市場規模、シェア、動向分析レポート：治療薬別、投与経路別、流通チャネル別、地域別、セグメント予測、2024年～2030年
出版日: 2023年12月15日
発行: Grand View Research
ページ情報: 英文 130 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インフルエンザ治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のインフルエンザ治療市場は、2024年から2030年にかけてCAGR 1.18%で拡大し、2030年までには64億4,000万米ドルに達する見込みです。

同市場の成長は、インフルエンザの有病率の上昇に加え、同疾患を治療するための効率的な治療薬に対するニーズの高まりに起因しています。さらに、主要企業は、インフルエンザ治療薬の承認に向けたFDAの絶え間ないイニシアチブのもと、正確な薬物療法に対する需要の高まりに対応するため、常に新規治療薬の開発に注力しています。その結果、世界の治療に対する絶え間ない需要が市場全体の成長に拍車をかけています。

さらに、季節性インフルエンザと呼吸器疾患の有病率の上昇が、新規治療薬の需要を押し上げています。CDCによると、米国におけるインフルエンザの負担は、2010年から2020年の間に年間900万人から4,100万人の疾病、14万から71万人の入院、1万2,000人から5万2,000人の死亡につながると推定されています。同様に、予備調査結果によると、2021年から2022年にかけて、約900万人が症状を訴え、約400万人の受診、10万人の入院、5,000人の死亡が報告されています。

市場成長の原動力となるのは、ウイルス感染症に対する革新的な治療薬の承認が進み、今後商品化が予定されていることです。例えば、2022年8月、Rocheは、48時間症状のある5～12歳の小児の急性インフルエンザ治療に使用されるXofluza（baloxavir marboxil）の米国FDA承認を発表しました。さらに、業界の大手企業は、2年から3年の間にウイルス感染症用の新薬をいくつか発表しており、大きな収益シェアを獲得するために、市場で事業を展開する他の小規模企業による新薬開拓の必要性を後押ししています。

さらに、COVID-19の大流行が市場の成長を大きく押し上げました。パンデミックの間、病気を効果的に管理する必要性から、新型コロナウイルスに対抗するための広域抗ウイルス薬の需要が急増しました。レムデシビル、ファビピラビル、オセルタミビル、各種併用療法などの薬剤がCOVID-19の治療に広く処方されるようになりました。さらに、政府はCOVID-19に対する新規治療薬の開発を促進するため、製薬会社により多くの資金を割り当てています。例えば、米国政府は2021年6月、抗ウイルス薬の発見、製造、開発を加速させるために30億米ドルを超える投資を行うことを発表しました。罹患率が上昇を続け、研究開発努力が強化されるにつれて、抗ウイルス薬の需要は今後2年から3年で増加すると予想されます。

さらに、主要参入企業は、国際的な足跡を拡大し、インフルエンザ治療市場における競合地位を維持するために、製品の上市、提携・協力、M&Aなど様々な戦略に取り組んでいます。例えば、2020年11月、ShionogiのXOFLUZA（Baloxavir Marboxil）がインフルエンザ予防薬としてFDAの承認を取得しました。同様に、2021年2月、FDAはBioCryst Pharmaceuticalsの製品であるペラミビル注射剤Rapivabの承認を拡大しました。同製品は、生後6カ月以上で2日間症状が持続した患者を対象に、合併症のない急性インフルエンザの治療に広く使用されています。

インフルエンザ治療薬市場レポートハイライト

  • 治療薬別では、オセルタミビルリン酸塩製剤が2023年に市場で最大の売上シェアを占めました。
  • 投与経路別では、投与が容易であることから経口医薬品の採用が増加しており、経口剤が2023年の売上高シェアで市場を独占しました。
  • 流通チャネル別では、入院患者数の増加と投薬のための病院薬局の利用が増加していることから、病院薬局セグメントが2023年の市場を独占しました。
  • 北米は、老舗企業の存在、季節性インフルエンザの流行の高まり、インフルエンザによる入院の増加により、2023年に最大のシェアを占めました。

目次

第1章 インフルエンザ治療市場：調査手法と範囲

第2章 インフルエンザ治療市場：エグゼクティブサマリー

  • 市場スナップショット
  • 治療と投与経路のスナップショット
  • 流通チャネルのスナップショット
  • 競合情勢のスナップショット

第3章 インフルエンザ治療市場の変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因分析
    • 新しくFDAが承認するインフルエンザ治療薬が増加
    • インフルエンザなどの伝染性呼吸器疾患の蔓延
  • 市場抑制要因分析
    • インフルエンザ治療に伴う複雑な症状
  • ポーターのファイブフォース分析
  • PESTLE分析

第4章 インフルエンザ治療市場：治療推定・動向分析

  • インフルエンザ治療市場：治療変動分析
  • ペラミビル
    • ペラミビル市場推計・予測、2018年～2030年
  • ザナミビル
    • ザナミビル市場推計・予測、2018年～2030年
  • バロキサビルマルボキシル
    • バロキサビルマルボキシル市場推計・予測、2018年～2030年
  • オセルタミビルリン酸塩
    • オセルタミビルリン酸塩市場推計・予測、2018年～2030年
  • その他
    • その他の市場推計・予測、2018年～2030年

第5章 インフルエンザ治療市場：投与経路の推定・動向分析

  • インフルエンザ治療薬市場：投与変動分析
  • オーラル
    • オーラル市場推計・予測、2018年～2030年
  • その他
    • その他の市場推計・予測、2018年～2030年

第6章 インフルエンザ治療薬市場：流通チャネルの推定・動向分析

  • インフルエンザ治療薬市場：流通チャネルの変動分析
  • 病院薬局
    • 病院薬局市場推計・予測、2018年～2030年
  • 小売薬局
    • 小売薬局市場推計・予測、2018年～2030年
  • オンライン薬局
    • オンライン薬局市場推計・予測、2018年～2030年

第7章 インフルエンザ治療市場：地域ビジネス分析

  • 地域市場のスナップショット
  • 北米
    • 北米のインフルエンザ治療市場推計・予測、2018年～2030年
    • 米国
    • カナダ
  • 欧州
    • 欧州のインフルエンザ治療市場、2018年～2030年
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • ノルウェー
    • スウェーデン
  • アジア太平洋地域
    • アジア太平洋のインフルエンザ治療市場、2018年～2030年
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • ラテンアメリカのインフルエンザ治療市場、2018年～2030年
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカのインフルエンザ治療市場、2018年～2030年
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 企業の分類
  • 戦略マッピング
    • 新しい発売
    • パートナーシップ
    • 取得
    • コラボレーション
  • 主要企業の市場シェア分析、2023年
  • 企業ヒートマップ分析
  • 企業プロファイル
    • Natco Pharma Limited
    • Novartis Ag
    • F. Hoffmann-la Roche Ltd
    • Biocryst Pharmaceuticals, Inc.
    • Sanofi
    • Gsk Plc.
    • Viatris Inc.（Mylan）
    • Teva Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited.
    • Astrazeneca
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Influenza Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 North America Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 5 North America Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 North America Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Canada Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 16 Europe Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 Europe Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Germany Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 Germany Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Germany Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 22 UK Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 UK Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 France Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 France Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 France Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Spain Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 28 Spain Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Spain Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Italy Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 Italy Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Denmark Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 34 Denmark Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Denmark Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Norway Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 37 Norway Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Norway Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Sweden Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 Sweden Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 Sweden Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Japan Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 47 Japan Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 Japan Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 China Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 50 China Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 China Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 India Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 India Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 India Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Australia Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 56 Australia Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Australia Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Korea Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 59 South Korea Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 South Korea Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Thailand Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Thailand Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Latin America Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 65 Latin America Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66 Latin America Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Latin America Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Brazil Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 69 Brazil Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 Mexico Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 72 Mexico Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 Mexico Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Argentina Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 75 Argentina Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 Argentina Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Africa Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 UAE Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 88 UAE Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 89 UAE Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global influenza treatment market- Key market driver analysis
  • Fig. 7 Global influenza treatment market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global influenza treatment market - Porter's analysis
  • Fig. 10 Global influenza treatment market - PESTEL analysis
  • Fig. 11 Global influenza treatment market: Treatment outlook key takeaways
  • Fig. 12 Global influenza treatment market: Treatment movement analysis
  • Fig. 13 Peramivir market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Zanamivir market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Baloxavir marboxil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Oseltamivir phosphate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Global influenza treatment market: Route of Administration outlook key takeaways
  • Fig. 19 Global influenza treatment market: Route of Administration movement analysis
  • Fig. 20 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Global influenza treatment market: Distribution Channel outlook key takeaways
  • Fig. 23 Global influenza treatment market: Distribution Channel movement analysis
  • Fig. 24 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Global influenza treatment market: Regional movement analysis
  • Fig. 29 North America influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Europe influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 UK influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 France influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Spain influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 China influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 India influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Strategy framework
目次
Product Code: GVR-4-68040-168-6

Influenza Treatment Market Growth & Trends:

The global influenza treatment market is expected to reach USD 6.44 billion by 2030, expanding at a CAGR of 1.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the rising prevalence of influenza aided by the rising need for efficient therapeutics to treat the condition. Furthermore, key players are constantly focusing on developing novel therapeutics to meet the rising demand for precise medication with constant initiative by the FDA for approval of influenza treatment drugs. As a result of which, the constant demand for treatment globally is fueling the growth of the overall market.

Additionally, the rising prevalence of seasonal flu and respiratory diseases has boosted the demand for novel therapeutics. According to CDC, it is estimated that the burden of flu in the U.S. had resulted in 9 million -41 million illnesses, 140,000 - 710,000 hospitalizations, and 12,000 - 52,000 deaths yearly between 2010 and 2020. Similarly, according to preliminary results around 9 million individuals had symptomatic illnesses, and approximately 4 million medical visits, 100,000 hospitalizations, and 5 thousand deaths were reported from 2021 to 2022.

The market growth is expected to be driven by the increasing approval and upcoming commercialization of innovative medications for viral infections. For instance, in August 2022, Roche announced the U.S. FDA approval for Xofluza (baloxavir marboxil), used for the treatment of acute influenza in children aged 5 to 12 years who have been symptomatic for 48 hours. Additionally, prominent players in the industry have introduced several novel medicines for viral infections within the span of 2 to 3 years propelling the need for the development of novel medication by other small players operating in the market in order to generate significant revenue share.

Moreover, the COVID-19 pandemic has significantly boosted the growth of the market. During the pandemic, the demand for broad-spectrum antiviral drugs to combat the novel coronavirus has surged due to the need to manage the disease effectively. Medications like Remdesivir, favipiravir, oseltamivir, and various combination therapies have become widely prescribed for treating COVID-19. Additionally, governments are allocating greater funding to pharmaceutical companies to expedite the development of novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government announced an investment of over USD 3 billion to accelerate the discovery, manufacturing, and development of antiviral medicines. As the incidence of the disease continues to rise and research and development efforts intensify, the demand for antiviral drugs is expected to increase in the next 2 to 3 years.

Furthermore, the key participants are engaged in various strategies such as product launches, partnerships & collaborations, and mergers & acquisitions, to expand their global footprints and maintain their competitive position in the influenza treatment market. For instance, in November 2020, Shionogi's XOFLUZA (Baloxavir Marboxil) received FDA approval for the prevention of influenza. Similarly, in February 2021, FDA expanded the approval of Rapivab which is a peramivir injection, a product of BioCryst Pharmaceuticals. The product is extensively used for treating acute uncomplicated influenza in 6 months of age & older patients who have been symptomatic for 2 days.

Influenza Treatment Market Report Highlights:

  • Based on treatment, the oseltamivir phosphate segment held the largest revenue share in 2023 in the market owing to the rising prevalence of influenza leading to increasing prescription of oseltamivir phosphate
  • Based on route of administration, the oral segment dominated the market with a revenue share in 2023 attributed to the increased adoption of oral drug products due to their ease of administration
  • On the basis of distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the rising hospitalization and use of hospital pharmacies for medication
  • North America held the largest share in 2023 owing to the presence of well-established players, the rising prevalence of seasonal flu, and an increased hospitalization due to the condition

Table of Contents

Chapter 1. Influenza Treatment Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Influenza Treatment Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Treatment and Route of Administration Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Influenza Treatment Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising new FDA-approved influenza treatment drugs
    • 3.4.2. Prevalence of contagious respiratory illness such as influenza
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complicated conditions associated with influenza treatment
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Influenza Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Influenza Treatment Market: Treatment Movement Analysis
  • 4.2. Peramivir
    • 4.2.1. Peramivir Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Zanamivir
    • 4.3.1. Zanamivir Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Baloxavir Marboxil
    • 4.4.1. Baloxavir Marboxil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oseltamivir Phosphate
    • 4.5.1. Oseltamivir Phosphate Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Influenza Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Influenza Treatment Market: Route of Administration Movement Analysis
  • 5.2. Oral
    • 5.2.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Others
    • 5.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Influenza Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Influenza Treatment Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacies
    • 6.4.1. Online Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Influenza Treatment Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Influenza Treatment Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. France
      • 7.3.4.1. France Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. Italy
      • 7.3.5.1. Italy Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Spain
      • 7.3.6.1. Spain Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Norway
      • 7.3.8.1. Norway Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-pacific Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Australia
      • 7.4.6.1. Australia Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.4.2. Key Country Dynamics
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
  • 8.3. Key Company Market Share Analysis, 2023
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Natco Pharma Limited
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Novartis Ag
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-la Roche Ltd
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Biocryst Pharmaceuticals, Inc.
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Sanofi
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Gsk Plc.
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Viatris Inc. (Mylan)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Daiichi Sankyo Company, Limited.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Astrazeneca
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives